Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV

• Main Authors: Randolph P. Matthews (Author), Wendy Ankrom (Author), Evan Friedman (Author), Deanne Jackson Rudd (Author), Yang Liu (Author), Robin Mogg (Author), Deborah Panebianco (Author), Inge De Lepeleire (Author), Magdalena Petkova (Author), Jay A. Grobler (Author), Selwyn Aubrey Stoch (Author), Marian Iwamoto (Author)
• Format: Book
• Published: Wiley, 2021-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Islatravir (MK‐8591) is a nucleoside analogue in development for the treatment and prevention of HIV‐1. Two phase 1 trials were conducted during initial evaluation of islatravir: rising single doses (Study 1) and rising multiple doses (Study 2) of oral islatravir in male and female particip...